Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
FEM1B (HGNC:3649) has emerged as a promising candidate in the genetic landscape of polycystic ovary syndrome (PCOS) (MONDO_0008487). Two independent multi‐patient studies have explored the possible role of FEM1B in PCOS pathogenesis. In these studies, both case–control and family‐based transmission analyses were performed, suggesting that variation in FEM1B may modulate disease risk. The investigations involved substantial cohorts, with one study reporting analyses in 287 cases (PMID:18757445) and another including 502 affected probands and sisters (PMID:20200332). These findings indicate that common variants in this gene are statistically associated with PCOS and related insulin‐secretion traits. Although the data promote an association, the underlying genetic mechanism remains to be definitively established.
The genetic evidence is primarily derived from candidate gene association approaches, which revealed that specific single nucleotide polymorphisms (SNPs) in FEM1B are significantly linked with altered risk for PCOS. For example, one study found that the FEM1B SNP rs10152450 was associated with a reduced likelihood of PCOS and correlated with improved beta‐cell function, while another study confirmed the involvement of FEM1B among other candidate genes through TDT analysis. The studies used robust statistical methodologies, and the replication across cohorts strengthens the clinical relevance of the association. However, the evidence does not include classic segregation data within extended pedigrees, which limits the overall strength of the genetic data. The candidate SNPs do not currently have corresponding HGVS coding variants reported in the context of PCOS. Overall, the genetic data support a moderate level of evidence linking FEM1B to PCOS.
It is important to note that a detailed analysis of variant types was not provided in the context of PCOS, and no single coding variant meeting HGVS criteria was reported in these studies. Instead, the association relies on identified SNP markers, which were consistently replicated in independent analyses. While the candidate gene studies present statistically significant associations, they do not fully recapitulate the spectrum of genetic alterations (e.g., missense, nonsense) typically seen in Mendelian disorders. These observations underscore the multifactorial nature of PCOS, where genetic susceptibility may involve multiple small‐effect variants. Thus, the genetic architecture of PCOS remains complex and multifactorial, and caution is warranted when interpreting the association. The current evidence supports further research to clarify the mechanistic role of FEM1B in disease pathogenesis.
The experimental or functional evidence directly supporting the association of FEM1B with PCOS is currently limited. Although FEM1B has been studied functionally in a separate context related to a syndromic neurodevelopmental disorder with clubfoot, no functional assessments have been performed to validate its role in PCOS. In the PCOS studies, the association analysis did not include cellular or animal models that could illuminate the underlying pathogenic mechanisms. This gap in functional data leaves the role of FEM1B in PCOS predominantly based on statistical associations rather than mechanistic insights. Consequently, while the genetic association is reproducible, the absence of corroborative experimental evidence diminishes the overall confidence in the pathogenic mechanism for PCOS. Further functional investigations are critically needed to bridge this gap.
In summary, the combined genetic evidence from candidate gene association studies provides moderate support for a link between FEM1B and polycystic ovary syndrome. Despite the strong statistical associations observed across independent cohorts, the lack of direct functional data and classical segregation evidence tempers the overall strength of the association. The available evidence indicates that FEM1B, through its involvement in insulin secretion and metabolic regulation, may contribute to PCOS susceptibility; however, further mechanistic studies are necessary. Clinicians should view this association as a potentially useful component in the complex genetic architecture of PCOS, meriting additional research to validate its clinical utility. Key take‑home: FEM1B represents a moderate yet promising genetic contributor to PCOS that could enhance diagnostic decision‑making once further validated.
Gene–Disease AssociationModerateTwo independent candidate gene association studies involving 287 cases (PMID:18757445) and 502 affected probands (PMID:20200332) support the association, although extended segregation data are limited. Genetic EvidenceModerateAssociation analyses identified multiple FEM1B SNPs with significant P-values in both case–control and family-based studies, implicating the gene in PCOS susceptibility despite the absence of detailed coding variant data. Functional EvidenceLimitedNo direct functional studies have been conducted to verify the role of FEM1B in PCOS, and available functional assessments pertain to a distinct phenotype, thereby limiting mechanistic support for the association. |